Nasdaq

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has ...
Nasdaq

Nicox Reports Positive Phase 3b Trial Results For NCX 470 In Intraocular Pressure Reduction

(RTTNews) - Nicox SA announced the results of the Whistler Phase 3b exploratory clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in ...
WTEN

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its ...
Seeking Alpha

Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans

Chaim Lebovits, President and CEO, stated that "our unwavering primary focus remains the execution of the clinical development plan for NurOwn and the initiation of our pivotal Phase 3b trial designed ...
Morningstar

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S.
WKRN-TV

Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the first patient has been screened in the Whistler Phase 3b clinical trial ...